Loading
A phase 2 trial of nab-paclitaxel, carboplatin and epirubicin in triple-negative breast cancer, run by Hebei Medical University Fourth Hospital, now recruiting.
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer is a phase 2, randomised interventional study registered as NCT04138719 by Hebei Medical University Fourth Hospital, with a registry enrolment figure of 520 participants, started 2019-11-20 and due to reach its primary completion in 2026-10-20. Interventions recorded: Nab-paclitaxel + Carboplatin; Nab-paclitaxel + Epirubicin. Conditions listed: Breast Cancer; Triple-negative Breast Cancer; Nab-paclitaxel. Triple-negative eligibility wording from the registry: "Histologically confirmed triple negative breast cancer;". Sites: China. No results are recorded here; the registry entry is the source.
Shares Nab-paclitaxel, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents and the tag tnbc-deep-dive.
Shares Epirubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents and the tag tnbc-deep-dive.
Shares Epirubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents and the tag tnbc-deep-dive.
Shares Nab-paclitaxel, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents and the tag tnbc-deep-dive.
Shares Nab-paclitaxel, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents and the tag tnbc-deep-dive.
Shares Epirubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents and the tag tnbc-deep-dive.
Shares Epirubicin, Nab-paclitaxel, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Carboplatin and the tag tnbc-deep-dive.